Buscador de publicacions

Publicacions

  • Eva Maria Grasa Bello, Seppälä J, Alonso-Solis A, Haapea M, Isohanni M, Miettunen J, Caro Mendivelso J, Almazan C, Rubinstein K, Caspi A, Unoka Z, Farkas K, Usall J, Ochoa S, van der Graaf S, Jewell C, Triantafillou A, Stevens M, Reixach E, Berdun-Marin S and Corripio I.

    m-RESIST, a Mobile Therapeutic Intervention for Treatment-Resistant Schizophrenia: Feasibility, Acceptability, and Usability Study.

    jmir formative research . 7: .

    [doi:10.2196/46179]

  • Serra C, Vila R, del Cacho N, Butjosa A, Manuel Abella Villena, Colomer A, Cunill R, Tena MC, Véliz DI, Bustos-Cardona T, Dolz M, Profep Group and Usall J.

    Association of perceived social support with sociodemographic, clinical, and psychosocial variables in patients with first-episode psychosis.

    JOURNAL OF PSYCHIATRIC RESEARCH . 162: 30-36. Nº de cites: 1

    [doi:10.1016/j.jpsychires.2023.04.008]

  • Abella M, Vila R, Serra C, Vallejo-Rius G, Colomer A, Rolduà-Ros J, del Cacho N, Butjosa A, Muñoz D, Cuevas-Esteban J, Profep G and Usall J.

    The relevance of processing speed in the functioning of people with first-episode psychosis

    JOURNAL OF PSYCHIATRIC RESEARCH . 160: 171-176.

    [doi:10.1016/j.jpsychires.2023.02.014]

  • Cuñat O, Del Hoyo-Buxo B, Vila R, Serra C, Butjosa A, del Cacho N, Colomer A, Dolz M, Cuevas-Esteban J, Iglesias M, Usall J and Profep Group.

    Negative symptoms in drug-naive patients with a first-episode psychosis (FEP)

    Asian Journal of Psychiatry . 81: 103448-103448. Nº de cites: 1

    [doi:10.1016/j.ajp.2023.103448]

  • Sánchez-Torres AM, Amoretti S, Enguita-Germán M, Mezquida G, Moreno-Izco L, Panadero-Gómez R, Rementería L, Toll A, Rodriguez-Jimenez R, Roldán A, Pomarol-Clotet E, Ibáñez Á, Usall J, Contreras F, Vieta E, López-Ilundain JM, Merchán-Naranjo J, González-Pinto A, Berrocoso E, Bernardo M and Cuesta MJ.

    Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study.

    EUROPEAN NEUROPSYCHOPHARMACOLOGY . 67: 53-65. Nº de cites: 3

    [doi:10.1016/j.euroneuro.2022.11.011]

  • Butjosa A, Usall J, Vila R, Mezquida G, Cuesta MJ, Rodríguez-Toscano E, Amoretti S, Lobo A, González-Pinto A, Espliego A, Corripio I, Vieta E, Baeza I, Bergé D, Bernardo M and PEPs Group.

    Impact of traumatic life events on clinical variables of individuals with first-episode psychosis and healthy controls.

    INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY . 69(1): 134-145. Nº de cites: 1

    [doi:10.1177/00207640211070398]

  • Saiz-Masvidal C, Contreras F, Soriano-Mas C, Mezquida G, Diaz-Caneja CM, Vieta E, Amoretti S, Lobo A, González-Pinto A, Janssen J, Sagué-Vilavella M, Castro-Fornieles J, Bergé D, Bioque M, Gonzalez-Lois N, Parellada M and Bernardo M.

    Structural covariance predictors of clinical improvement at 2-year follow-up in first-episode psychosis.

    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY . 120: 110645-110645. Nº de cites: 1

    [doi:10.1016/j.pnpbp.2022.110645]

  • Cunill R, Vives L, Pla M, Usall J and Castells X.

    Relationship between obsessive compulsive symptomatology and severity of psychotic symptoms in schizophrenia: Meta-analysis and meta-regression analysis.

    SCHIZOPHRENIA RESEARCH . 251: 37-45. Nº de cites: 4

    [doi:10.1016/j.schres.2022.12.013]

  • Ferrer-Quintero M, Verdaguer M, Marina Esteban Sanjusto, Serra C, Usall J, Ochoa S, Bighelli I and García-Mieres H.

    Sex differences in symptomatology in people with schizophrenia and other psychotic disorders: protocol for a systematic review and pairwise meta-analysis of observational studies.

    BJPsych Open . 8(6): .

    [doi:10.1192/bjo.2022.596]

  • Cuesta MJ, Ballesteros A, Sánchez-Torres AM, Amoretti S, López-Ilundain JM, Merchán-Naranjo J, González-Ortega I, Salgado P, Rodriguez-Jimenez R, Roldán-Bejarano A, Sarró S, Ibáñez Á, Usall J, Escartí MJ, Moreno-Izco L, Mezquida G, Parellada M, González-Pinto A, Berrocoso E and Bernardo M.

    Relapse of first-episode schizophrenia patients and neurocognitive impairment: The role of dopaminergic and anticholinergic burden

    SCHIZOPHRENIA RESEARCH . 248: 331-340.

    [doi:10.1016/j.schres.2022.09.014]